keynote-224: improving hcc outcomes with pembrolizumab
Published 6 years ago • 179 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
3:22
keynote-224: pembrolizumab monotherapy for previously untreated hcc
-
3:02
keynote-224: second-line pembrolizumab’s value in hcc
-
2:25
keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma
-
1:11
dr. zhu discusses findings of the keynote-224 in hcc
-
2:09
keynote-240: pembrolizumab in advanced hcc
-
6:39
emerging second-line therapies in hcc
-
6:03
two options for checkpoint inhibition in hcc
-
2:08
dr. finn on studies of pembrolizumab in hepatocellular carcinoma
-
4:32
first-line regorafenib 80mg/day with pembrolizumab in advanced hcc
-
1:18
andrew zhu, md, phd, on the effectiveness of pembrolizumab in hcc patients treated with sorafenib
-
1:02
dr. kudo discusses tace plus sorafenib in hcc
-
6:30
treatment strategies for early-stage hcc
-
5:39
hcc: criteria for resection and adjuvant therapy
-
2:58
dr. bellmunt discusses follow-up data for pembrolizumab vs chemotherapy in bladder cancer
-
15:26
perspectives on the future treatment of hcc
-
9:11
transitioning to systemic therapy in hcc
-
1:06
dr. whitman on the role of pembrolizumab in melanoma